Platform Technology Overview
CoImmune® is developing two cellular platform technologies
Our CAR-CIK technology is currently being developed for liquid tumors and our RNA-loaded dendritic cell technology for solid tumors. Our first CAR-CIK product is currently in clinical trials in pediatric and adult acute lymphoblastic leukemia and our first dendritic cell product is currently in a clinical trial in advanced metastatic renal cell carcinoma.
Allogeneic CAR-modified cytokine induced killer (CIK) cell*
- Multiple killing mechanisms
- Strong efficacy in prior trial with little to no toxicity
- Allogeneic with off-the-shelf availability
- Proprietary non-viral gene transfer
- Broad applicability in both liquid and solid tumors
- Lower cost of goods compared to approved CAR-T
*Experimental Hematology 34 (2006) 1218-1228
**J Immunother (2011) 34 (1):45-57
Autologous RNA-loaded dentritic cells **
- Targets all neoantigens without the need to identify them
- Strong efficacy in prior trial
- Little to no toxicity
- Broadly applicable to all solid tumors
